Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

NK Cell Therapy for Glioblastoma via Intrathecal Delivery

Written by Dr. David Greene, MD, PhD, MBA on July 15, 2026

Table of Contents

A glioblastoma diagnosis brings patients and families to a crossroads almost immediately: standard treatment — surgery, radiation, and chemotherapy — offers a real but often limited benefit, and many people start researching what else exists. Natural killer (NK) cell therapy is one of the immunotherapy approaches generating interest in this space, particularly because of its potential delivery.

A common question that comes up in that research is why some clinicians favor injecting NK cells directly into the cerebrospinal fluid — a method known as intrathecal administration — rather than giving them through a standard intravenous (IV) infusion. The short answer involves a structure called the blood-brain barrier. The fuller answer requires understanding what NK cells are, what the current research actually shows, and where the open questions remain.

This article breaks down the biology, the delivery methods under investigation, and the current state of the evidence — so patients and families can ask better questions of their care team, whichever path they’re considering.

What Makes Glioblastoma So Difficult to Treat?

Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults. It grows quickly, infiltrates surrounding brain tissue in finger-like projections that are difficult to fully remove surgically, and tends to recur even after aggressive treatment. Median survival with standard therapy — surgical resection followed by radiation and temozolomide chemotherapy — remains measured in months to a small number of years for most patients, which is why research into additional or alternative approaches, including immunotherapy, has intensified.

One of the central obstacles to treating glioblastoma with drugs or cell therapies is anatomical: the blood-brain barrier.

The Blood-Brain Barrier, Explained

The blood-brain barrier (sometimes called the hematoencephalic barrier) is a tightly regulated layer of cells lining the blood vessels of the brain and spinal cord. It exists to protect the central nervous system from toxins, pathogens, and fluctuations in the bloodstream — but that same protection makes it difficult for many cancer therapies, including antibodies, chemotherapy drugs, and immune cells given intravenously, to reach a brain tumor in sufficient quantity.

Research on CAR-modified NK cells illustrates this problem directly. In preclinical models, NK cells were engineered to target tumor markers. They were delivered intravenously and largely failed to reach intracranial tumors in effective numbers, and did not produce a therapeutic benefit against brain tumors without additional measures to help them cross the barrier. This is a major reason researchers have explored routes of delivery that bypass the barrier entirely rather than trying to cross it from the bloodstream.

What Are NK Cells, and Why Are They Being Studied for Brain Tumors?

Natural killer cells are a category of white blood cells that are part of the innate immune system — the body’s first line of defense. Unlike T cells, which need to recognize a specific antigen before they can act, NK cells can identify and kill abnormal cells, including virus-infected cells and certain cancer cells, without prior sensitization. This makes them an attractive candidate for “off-the-shelf” cellular immunotherapy.

Because NK cells operate as part of a larger, interconnected immune network, the broader effects of stem cells on immune system function offer useful context for where NK-based approaches fit within cellular and regenerative medicine more generally.

In the context of glioblastoma specifically:

Some studies have found meaningful NK cell infiltration into glioma tissue, while others report very limited infiltration, particularly in higher-grade or more aggressive tumors — the tumor microenvironment itself appears to suppress NK cell activity in many cases.

Preclinical studies in rodent models have shown that NK cells delivered directly into the brain or cerebrospinal fluid can migrate to tumor sites and reduce tumor burden, as tracked by MRI and fluorescent imaging.

Ongoing early-phase human trials are testing NK cells delivered intracranially or intraventricularly (through a surgically implanted Ommaya reservoir), sometimes in combination with antibody therapies, specifically because systemic IV delivery has underperformed in this tumor type.

None of this means NK cell therapy is a proven treatment for glioblastoma. It means the underlying biological rationale — that NK cells can kill glioma cells, and that getting them past the blood-brain barrier improves their chances of doing so — is active, credible, and evolving science, primarily being tested in Phase I and Phase I/II clinical trials rather than delivered as routine, guideline-endorsed care.

Delivery Routes: IV vs. Intrathecal vs. Intracranial

Not all NK cell administration methods are the same, and the differences matter for a tumor located in the central nervous system.

Delivery Route

How It’s Given

Blood-Brain Barrier Impact

Typical Use Case

Intravenous (IV)

Infused into the bloodstream through a vein

Must cross the blood-brain barrier to reach brain tissue; research suggests this happens inefficiently for CNS tumors

More established for cancers outside the CNS (e.g., leukemia, some solid tumors); often combined with other routes for brain tumors

Intrathecal

Injected into the cerebrospinal fluid, usually via lumbar puncture (spinal tap)

Bypasses the barrier by entering the CSF directly

Under investigation for CNS-involving cancers and CNS-directed cell/drug therapies

Intracranial / Intraventricular

Delivered directly into the tumor cavity or brain ventricles, often via a surgically placed reservoir

Bypasses the barrier entirely; most direct route to the tumor site

Used in several ongoing Phase I glioblastoma trials, sometimes alongside IV dosing

Clinical trials currently underway for NK cell-based therapies in brain tumors often use combination protocols — for example, cerebrospinal fluid or intracranial dosing paired with a separate intravenous infusion — rather than relying on one route alone. This reflects an evolving understanding that different routes may serve different purposes: local, high-concentration delivery to the tumor site, alongside systemic immune support.

Why Intrathecal Delivery Requires Specialized Expertise

Because intrathecal administration involves accessing the spinal canal, it is a medical procedure with real risks — including headache, infection, bleeding, and, rarely, more serious neurological complications — that must be weighed against any potential benefit. For this reason, it should only be performed by a clinician specifically trained in the technique, typically an anesthesiologist or interventional specialist experienced in spinal procedures, working as part of a coordinated care team that includes the patient’s oncology providers.

Experience matters here in a very concrete way: familiarity with positioning, sterile technique, and recognizing complications early all affect how safely the procedure is performed. Patients evaluating any clinic offering intrathecal cell therapy should feel comfortable asking directly about the proceduralist’s training, case volume, and safety record — reviewing how intrathecal stem cell treatment protocols offered in clinics across Mexico and Pakistan are structured can offer a useful point of comparison.

What the Evidence Actually Shows (and Doesn't)

It’s easy for the promise of a therapy to outrun the data behind it, especially in a fast-moving field like cellular immunotherapy. Here’s a more precise picture of where things stand:

Preclinical (animal model) evidence for NK cell migration and tumor reduction after direct CNS or intrathecal delivery is genuinely encouraging in several published studies.

Human clinical trials of NK cell therapy for glioblastoma — including intracranial, intraventricular, and combined intrathecal/IV protocols — are underway, but the large majority are still in Phase I or Phase I/II, meaning the primary goals are establishing safety and tolerable dosing, not yet confirming a survival benefit.

No NK cell therapy is currently FDA-approved as a standard treatment for glioblastoma. Temozolomide, radiation, and surgical resection remain the established standard of care; NK cell approaches are investigational and typically available only through clinical trials or specialized treatment centers; understanding the FDA's 351 vs. 361 classification framework for human cell and tissue-based products helps clarify how these therapies are currently regulated in the United States.

Claims that intrathecal delivery produces "better results" than IV delivery are supported as a mechanistic rationale — cells reach the CNS more directly — but head-to-head outcome data in glioblastoma patients specifically are still limited. This is an area of legitimate ongoing research, not a settled conclusion.

Patients should treat any claim of guaranteed or dramatic outcomes with appropriate skepticism, and ask providers to distinguish clearly between “this is biologically plausible and being studied” and “this is proven to extend survival.”

How This Fits Into a Patient's Broader Care Plan

For most patients, NK cell therapy — however it’s delivered — is not a replacement for standard glioblastoma treatment but a potential addition to it, typically considered after surgery, radiation, and chemotherapy, or in cases of recurrence. Regenerative and cellular medicine clinics, including R3 Stem Cell’s Tijuana, Mexico location, have incorporated NK cell protocols, including cerebrospinal fluid-based delivery performed by anesthesiologists experienced in the technique, as part of individualized treatment planning for appropriate candidates. Patients researching stem cell treatment options available in Mexico should understand how such protocols are structured and monitored in that setting. As with any investigational or adjunct therapy, the right first step is a thorough discussion with the patient’s own oncology team about how such an option would interact with their existing treatment, what monitoring would look like, and what outcomes are realistic to expect.

Knowing how to choose the right regenerative medicine clinic matters as much as understanding the therapy itself, particularly for a diagnosis as serious as glioblastoma.

Questions Worth Asking Any Provider

Is this therapy part of a registered clinical trial, or an individualized treatment protocol outside of one?

What published or trial data exists specifically for this cancer type and this delivery route?

Who performs the procedure, and what is their specific experience with intrathecal or intracranial cell delivery?

How will this be coordinated with my existing oncology care, rather than replacing it?

What are the realistic, evidence-based expectations for benefit, and what are the risks?

The Bottom Line

The rationale for intrathecal NK cell delivery in glioblastoma is grounded in real, well-documented biology: the blood-brain barrier limits how well IV-delivered cells reach brain tumors, and bypassing it via the cerebrospinal fluid is a logical — and actively studied — workaround. What isn’t yet settled is how much of a clinical benefit this approach delivers compared with other routes, since most of the supporting evidence remains in the preclinical and early clinical trial stages. Patients considering this option deserve a clear-eyed picture of both the promise and the limits of the current evidence, delivered by a care team willing to answer direct questions about training, data, and realistic outcomes.

Contact Us